Ovarian cancer: emerging molecular-targeted therapies

References

• RukazenkovYSpeakeGMarshallGEpidermal growth factor receptor tyrosine kinase inhibitors: similar but different?Anticancer Drugs2009201085686619657272
   PubMed Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialLancet2012379981663364022257673
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• NiloffJMBastRCJrSchaetzlEMKnappRCPredictive value of CA 125 antigen levels in second-look procedures for ovarian cancerAm J Obstet Gynecol198515179819863157319
   PubMed Web of Science ®Google Scholar
• NiloffJMKnappRCSchaetzlEReynoldsCBastRCJrCA 125 antigen levels in obstetric and gynecologic patientsObstet Gynecol19846457037076208522
   PubMed Web of Science ®Google Scholar
• NiloffJMKnappRCLavinPTThe CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancerAm J Obstet Gynecol1986155156603460341
   PubMed Web of Science ®Google Scholar
• BastRCJrHennessyBMillsGBThe biology of ovarian cancer: new opportunities for translationNat Rev Cancer20099641542819461667
   PubMed Web of Science ®Google Scholar
• FerraraNKerbelRSAngiogenesis as a therapeutic targetNature2005438707096797416355214
   PubMed Web of Science ®Google Scholar
• FraserHMWilsonHMorrisKDSwanstonIWiegandSJVascular endothelial growth factor Trap suppresses ovarian function at all stages of the luteal phase in the macaqueJ Clin Endocrinol Metab200590105811581816046580
   PubMed Web of Science ®Google Scholar
• FraserHMDuncanWCVascular morphogenesis in the primate ovaryAngiogenesis20058210111616240058
   PubMedGoogle Scholar
• BossEAMassugerLFThomasCMGeurts-MoespotABoonstraHSweepCGVascular endothelial growth factor in ovarian cyst fluidCancer200191237137711180084
   PubMed Web of Science ®Google Scholar
• ShenGHGhazizadehMKawanamiOPrognostic significance of vascular endothelial growth factor expression in human ovarian carcinomaBr J Cancer200083219620310901370
   PubMed Web of Science ®Google Scholar
• HeflerLAMusteaAKonsgenDVascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancerClin Cancer Res200713389890117289883
   PubMed Web of Science ®Google Scholar
• ChenHYeDXieXChenBLuWVEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinomaGynecol Oncol200494363063515350351
   PubMed Web of Science ®Google Scholar
• KumaranGCJaysonGCClampARAntiangiogenic drugs in ovarian cancerBr J Cancer200910011719002176
   PubMed Web of Science ®Google Scholar
• DavisMIHuntJPHerrgardSComprehensive analysis of kinase inhibitor selectivityNat Biotechnol201129111046105122037378
   PubMed Web of Science ®Google Scholar
• KaramanMWHerrgardSTreiberDKA quantitative analysis of kinase inhibitor selectivityNat Biotechnol200826112713218183025
   PubMed Web of Science ®Google Scholar
• PerrenTJSwartAMPfistererJA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med2011365262484249622204725
   PubMed Web of Science ®Google Scholar
• BurgerRABradyMFBookmanMAIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
   PubMed Web of Science ®Google Scholar
• FriedlanderMHancockKCRischinDA Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecol Oncol20101191323720584542
   PubMed Web of Science ®Google Scholar
• RamasubbaiahRPerkinsSMSchilderJSorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology GroupGynecol Oncol2011123349950421955480
   PubMed Web of Science ®Google Scholar
• AnnunziataCMWalkerAJMinasianLVandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2Clin Cancer Res201016266467220068097
   PubMed Web of Science ®Google Scholar
• MakhijaSAmlerLCGlennDClinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancerJ Clin Oncol20102871215122319901115
   PubMed Web of Science ®Google Scholar
• MurphyMStordalBErlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic reviewDrug Resist Updat201114317719021435938
   PubMed Web of Science ®Google Scholar
• LedermannJARajaFATargeted trials in ovarian cancerGynecol Oncol2010119115115620591473
   PubMed Web of Science ®Google Scholar
• WienerJRWindhamTCEstrellaVCActivated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancersGynecol Oncol2003881737912504632
   PubMed Web of Science ®Google Scholar
• WeisSCuiJBarnesLChereshDEndothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasisJ Cell Biol2004167222322915504909
   PubMed Web of Science ®Google Scholar
• MukhopadhyayDTsiokasLSukhatmeVPWild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expressionCancer Res19955524616161658521408
   PubMed Web of Science ®Google Scholar
• MukhopadhyayDTsiokasLZhouXMFosterDBruggeJSSukhatmeVPHypoxic induction of human vascular endothelial growth factor expression through c-Src activationNature199537565325775817540725
   PubMed Web of Science ®Google Scholar
• WakaharaKKobayashiHYagyuTTransforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cellsJ Cell Biochem200493343745315372629
   PubMed Web of Science ®Google Scholar
• LeXFBastRCJrSrc family kinases and paclitaxel sensitivityCancer Biol Ther201112426026921646863
   PubMed Web of Science ®Google Scholar
• CooperCSParkMBlairDGMolecular cloning of a new transforming gene from a chemically transformed human cell lineNature1984311598129336590967
   PubMed Web of Science ®Google Scholar
• NataliPGPratMNicotraMROverexpression of the met/HGF receptor in renal cell carcinomasInt J Cancer19966932122178682590
   PubMed Web of Science ®Google Scholar
• Di RenzoMFOliveroMKatsarosDOverexpression of the Met/HGF receptor in ovarian cancerInt J Cancer19945856586628077049
   PubMed Web of Science ®Google Scholar
• SawadaKRadjabiARShinomiyaNc-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasionCancer Res20076741670167917308108
   PubMed Web of Science ®Google Scholar
• TrusolinoLBertottiAComoglioPMMET signalling: principles and functions in development, organ regeneration and cancerNat Rev Mol Cell Biol2010111283484821102609
   PubMed Web of Science ®Google Scholar
• GherardiEBirchmeierWBirchmeierCVandeWGTargeting MET in cancer: rationale and progressNat Rev Cancer20121228910322270953
   PubMed Web of Science ®Google Scholar
• GiordanoSCorsoSConrottoPThe semaphorin 4D receptor controls invasive growth by coupling with MetNat Cell Biol20024972072412198496
   PubMed Web of Science ®Google Scholar
• MitraAKSawadaKTiwariPMuiKGwinKLengyelELigand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasisOncogene201130131566157621119598
   PubMed Web of Science ®Google Scholar
• BussolinoFDi RenzoMFZicheMHepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growthJ Cell Biol199211936296411383237
   PubMed Web of Science ®Google Scholar
• ZhangYWSuYVolpertOVVande WoudeGFHepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulationProc Natl Acad Sci U S A200310022127181272314555767
   PubMed Web of Science ®Google Scholar
• SulpiceEDingSMuscatelli-GrouxBCross-talk between the VEGF-A and HGF signalling pathways in endothelial cellsBiol Cell2009101952553919281453
   PubMed Web of Science ®Google Scholar
• BirchmeierCBirchmeierWGherardiEVande WoudeGFMet, metastasis, motility and moreNat Rev Mol Cell Biol200341291592514685170
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
   PubMed Web of Science ®Google Scholar
• RoyRChunJPowellSNBRCA1 and BRCA2: different roles in a common pathway of genome protectionNat Rev Cancer2012121687822193408
   PubMed Web of Science ®Google Scholar
• CassIBaldwinRLVarkeyTMoslehiRNarodSAKarlanBYImproved survival in women with BRCA-associated ovarian carcinomaCancer20039792187219512712470
   PubMed Web of Science ®Google Scholar
• TanDSRothermundtCThomasKBRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutationsJ Clin Oncol200826345530553618955455
   PubMed Web of Science ®Google Scholar
• TommiskaJBartkovaJHeinonenMThe DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancerOncogene2008272501250617982490
   PubMed Web of Science ®Google Scholar
• SullivanAYuilleMRepellinCConcomitant inactivation of p53 and Chk2 in breast cancerOncogene20022191316132411857075
   PubMed Web of Science ®Google Scholar
• KayeSBLubinskiJMatulonisUPhase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerJ Clin Oncol201230437237922203755
   PubMed Web of Science ®Google Scholar
• NorquistBWurzKAPennilCCSecondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomasJ Clin Oncol201129223008301521709188
   PubMed Web of Science ®Google Scholar
• KonstantinopoulosPACannistraSAComparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trialJ Clin Oncol201230434735022203759
   PubMed Web of Science ®Google Scholar
• BaldwinRLNemethETranHBRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based studyCancer Res200060195329533311034065
   PubMed Web of Science ®Google Scholar
• ChobanianNHGreenbergVLGassJMDesimoneCPVan NagellJRZimmerSGHistone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 statusAnticancer Res2004242B53954515160991
   PubMed Web of Science ®Google Scholar
• SonnemannJHulsISiglerMHistone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cellsOncol Rep200820121922418575740
   PubMed Web of Science ®Google Scholar
• HoffmanMABlessingJANunezERA phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group studyGynecol Oncol200181343343511371134
   PubMed Web of Science ®Google Scholar
• HoffmanMABlessingJAMorganMPhase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group StudyGynecol Oncol200079346346511104620
   PubMed Web of Science ®Google Scholar
• MarksPAXuWSHistone deacetylase inhibitors: Potential in cancer therapyJ Cell Biochem2009107460060819459166
   PubMed Web of Science ®Google Scholar
• EngelmanJATargeting PI3K signalling in cancer: opportunities, challenges and limitationsNat Rev Cancer20099855056219629070
   PubMed Web of Science ®Google Scholar
• AltomareDAWangHQSkeleKLAKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growthOncogene200423345853585715208673
   PubMed Web of Science ®Google Scholar
• HanrahanAJSchultzNWestfalMLGenomic complexity and AKT dependence in serous ovarian cancerCancer Discov201221566722328975
   PubMed Web of Science ®Google Scholar
• PhilpAJCampbellIGLeetCThe phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumorsCancer Res200161207426742911606375
   PubMed Web of Science ®Google Scholar
• BellacosaAdeFDGodwinAKMolecular alterations of the AKT2 oncogene in ovarian and breast carcinomasInt J Cancer19956442802857657393
   PubMed Web of Science ®Google Scholar
• ChengJQGodwinAKBellacosaAAKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomasProc Natl Acad Sci U S A19928919926792711409633
   PubMed Web of Science ®Google Scholar
• JankuFWhelerJJWestinSNPI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA MutationsJ Clin Oncol201230877778222271473
   PubMed Web of Science ®Google Scholar
• PerkinsNDThe diverse and complex roles of NF-kappaB subunits in cancerNat Rev Cancer201212212113222257950
   PubMed Web of Science ®Google Scholar
• WhiteKLRiderDNKalliKRKnutsonKLJarvikGPGoodeELGenomics of the NF-kappaB signaling pathway: hypothesized role in ovarian cancerCancer Causes Control201122578580121359843
   PubMed Web of Science ®Google Scholar
• SavvariPPeitsidisPAlevizakiMDimopoulosMAAntsaklisAPapadimitriouCAParaneoplastic humorally mediated hypercalcemia induced by parathyroid hormone-related protein in gynecologic malignancies: a systematic reviewOnkologie2009328–951752319745599
   PubMedGoogle Scholar
• AgouniASourbierCDanilinSParathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa BCarcinogenesis20072891893190117468516
   PubMed Web of Science ®Google Scholar
• ShawRJCantleyLCDecoding key nodes in the metabolism of cancer cells: sugar and spice and all things niceF1000 Biol Rep20124222242042
   PubMedGoogle Scholar
• DeberardinisRJLumJJThompsonCBPhosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growthJ Biol Chem200628149373723738017030509
   PubMed Web of Science ®Google Scholar
• WangHQAltomareDASkeleKLPositive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cellsOncogene200524223574358215806173
   PubMed Web of Science ®Google Scholar
• Brahimi-HornMCBellotGPouyssegurJHypoxia and energetic tumour metabolismCurr Opin Genet Dev2011211677221074987
   PubMed Web of Science ®Google Scholar
• DenkoNCHypoxia, HIF1 and glucose metabolism in the solid tumourNat Rev Cancer20088970571319143055
   PubMed Web of Science ®Google Scholar
• LuoWHuHChangRPyruvate kinase M2 is a PHD3- stimulated coactivator for hypoxia-inducible factor 1Cell2011145573274421620138
   PubMed Web of Science ®Google Scholar
• WarburgOOn respiratory impairment in cancer cellsScience1956124321526927013351639
   PubMed Web of Science ®Google Scholar
• SeeberLMHorreeNVooijsMAThe role of hypoxia inducible factor-1alpha in gynecological cancerCrit Rev Oncol Hematol201178317318420627616
   PubMed Web of Science ®Google Scholar
• RapisardaAUranchimegBSordetOPommierYShoemakerRHMelilloGTopoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implicationsCancer Res20046441475148214983893
   PubMed Web of Science ®Google Scholar
• IsaacsJSJungYJMimnaughEGMartinezACuttittaFNeckersLMHsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathwayJ Biol Chem200227733299362994412052835
   PubMed Web of Science ®Google Scholar
• HudsonCCLiuMChiangGGRegulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycinMol Cell Biol200222207004701412242281
   PubMed Web of Science ®Google Scholar
• PoreNJiangZGuptaACernigliaGKaoGDMaityAEGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanismsCancer Res20066663197320416540671
   PubMed Web of Science ®Google Scholar
• NiemanKMKennyHAPenickaCVAdipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growthNat Med201117111498150322037646
   PubMed Web of Science ®Google Scholar
• BlackmanRKCheung-OngKGebbiaMMitochondrial electron transport is the cellular target of the oncology drug elesclomolPLoS One201271e2979822253786
   PubMed Web of Science ®Google Scholar
• FuldaSGalluzziLKroemerGTargeting mitochondria for cancer therapyNat Rev Drug Discov20109644746420467424
   PubMed Web of Science ®Google Scholar
• LimMCSongYJSeoSSYooCWKangSParkSYResidual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancerOnkologie201033632433020523098
   PubMedGoogle Scholar
• DahiyaNMorinPJMicroRNAs in ovarian carcinomasEndocr Relat Cancer2010171F77F8919903743
   PubMed Web of Science ®Google Scholar
• SchroederAHellerDAWinslowMMTreating metastatic cancer with nanotechnologyNat Rev Cancer2012121395022193407
   PubMed Web of Science ®Google Scholar
• PolterauerSVergoteIConcinNPrognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA–IV: analysis of the OVCAD dataInt J Gynecol Cancer201222338038522266934
   PubMed Web of Science ®Google Scholar